Related Experiment Video

Updated: Mar 28, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K

[Association of ADAMTS-1 gene polymorphisms with ischemic stroke caused by large artery atherosclerosis]

Chenling Lyu1, Yawen Chen, Min Zhu

  • 1Department of Neurology, Taizhou Hospital Affiliated to Wenzhou Medical University, Taizhou, Zhejiang 317000, P.R. China. jinxp155@aliyun.com.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics
|December 15, 2015
PubMed

Insights

Polymorphisms in the ADAMTS-1 gene, specifically rs402007, are linked to large artery atherosclerosis ischemic stroke. The C allele may increase susceptibility to this stroke subtype.

Area of Science:

  • Genetics
  • Neurology
  • Cardiovascular Disease

Background:

  • Large artery atherosclerosis (LAA) is a significant cause of ischemic stroke.
  • Genetic factors play a role in the development of LAA-related ischemic stroke.
  • The ADAMTS-1 gene is a potential candidate gene influencing vascular disease.

Purpose of the Study:

  • To investigate the association between specific polymorphisms in the ADAMTS-1 gene and ischemic stroke caused by LAA.
  • To identify potential genetic risk factors for LAA-related ischemic stroke.

Main Methods:

  • Genotyping of single nucleotide polymorphisms (SNPs) rs416905 (T/C) and rs402007 (G/C) in the ADAMTS-1 gene.
  • Polymerase chain reaction and DNA sequencing were used for genotyping.
  • Comparison of genotype and allele frequencies between 767 patients with LAA ischemic stroke and 506 controls.

Main Results:

  • Significant differences in the frequencies of the rs402007 GC+CC genotype and C allele were observed between patients and controls.
  • Binary logistic regression confirmed the significant association of rs402007 polymorphisms with LAA ischemic stroke (P=0.001, OR=1.521).
  • rs416905 and rs402007 SNPs were in complete linkage disequilibrium.

Conclusions:

  • Polymorphisms in the ADAMTS-1 gene, particularly at the rs402007 locus, are associated with ischemic stroke due to LAA.
  • The C allele of the rs402007 polymorphism may represent a susceptibility factor for LAA-related ischemic stroke.
Abstract

More Related Videos

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

10.9K
Endothelin-1 Induced Middle Cerebral Artery Occlusion Model for Ischemic Stroke with Laser Doppler Flowmetry Guidance in Rat07:26

Endothelin-1 Induced Middle Cerebral Artery Occlusion Model for Ischemic Stroke with Laser Doppler Flowmetry Guidance in Rat

Published on: February 16, 2013

20.8K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
745
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.0K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
582